Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service peripheral arterial intervention cases in Minnesota: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 8% on average (237 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 21 | 2,379 | 49% |
| 2020 | 17 | 2,026 | 52% |
| 2021 | 12 | 1,870 | 56% |
| 2022 | 14 | 1,707 | 59% |
| 2023 | 15 | 1,755 | 62% |
| 2024 | 9 | 1,536 | 64% |
| 2025 from claims | – | 2,361 2,167–2,498 | 65% |
| 2026 forecast | – | 2,648 2,330–3,055 | 61% |
| 2027 forecast | – | 2,723 2,328–3,245 | 61% |
| 2028 forecast | – | 2,801 2,337–3,429 | 61% |
| 2029 forecast | – | 2,880 2,352–3,612 | 60% |
| 2030 forecast | – | 2,962 2,373–3,796 | 60% |
Iliac, femoropopliteal, and tibial angioplasty, stenting, atherectomy. Professional codes (what the surgeon bills): CPT 37220, 37221, 37224, 37225, 37226, 37227, 37228, 37229, 37230, 37231; the hospital bills MS-DRG 252, 253, 254.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Minnesota; 6 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 50% inpatient hospital, 50% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Illinois | 47 | 6,194−7.5%/yr | −7.5%/yr | 4.3 | 41% | 6,330 in 2030+0.4%/yr |
| Michigan | 34 | 4,986−13%/yr | −13%/yr | 5.6 | 65% | 5,540 in 2030+1.8%/yr |
| Ohio | 26 | 3,751−11%/yr | −11%/yr | 3.2 | 4% | 3,700 in 2030−0.2%/yr |
| Indiana | 18 | 2,941−9.6%/yr | −9.6%/yr | 4.0 | 16% | 2,980 in 2030+0.2%/yr |
| Missouri | 19 | 2,750−14%/yr | −14%/yr | 4.2 | 21% | 3,390 in 2030+3.5%/yr |
| Kansas | 13 | 2,258−6.3%/yr | −6.3%/yr | 5.4 | 53% | 2,010 in 2030−1.9%/yr |
| Wisconsin | 15 | 1,979−9.4%/yr | −9.4%/yr | 3.3 | 2% | 2,150 in 2030+1.4%/yr |
| South Dakota | 13 | 1,501−0.4%/yr | −0.4%/yr | 11.2 | 76% | 1,800 in 2030+3%/yr |
| Nebraska | 9 | 1,170−1.7%/yr | −1.7%/yr | 4.4 | 62% | 2,150 in 2030+11%/yr |
| Iowa | 8 | 1,121−12%/yr | −12%/yr | 2.4 | 11% | 1,490 in 2030+4.9%/yr |
| North Dakota | 5 | 361−11%/yr | −11%/yr | 3.5 | 0% | 220 in 2030−8.1%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Dialysis access | 31 | 1,328−18%/yr | −18%/yr | 3.10.6× | 42% | 1,660 in 2030+3.8%/yr |
| Superficial venous ablation | 14 | 975−3.2%/yr | −3.2%/yr | 2.00.6× | 88% | 1,710 in 2030+9.8%/yr |
| Thrombectomy, IVC filters & venous stents | 3 | 534−2.8%/yr | −2.8%/yr | 1.20.8× | 0% | 1,150 in 2030+14%/yr |
| Carotid revascularization | 6 | 404−8.6%/yr | −8.6%/yr | 0.90.7× | 0% | 530 in 2030+4.6%/yr |
| Aortic endografts (EVAR/TEVAR) | 0 | 187−8.9%/yr | −8.9%/yr | 0.40.9× | 0% | 190 in 2030+0.2%/yr |
Peripheral arterial intervention in every state, and its device makers · Every procedure market in Minnesota · Every state · Compare with Illinois
Medtronic leads with 33% of company spending on these surgeons in 2025, −15 pts on 2024.
In 2025, 9 companies reported engagement with Minnesota’s surgeons worth $12K in consulting, speaking, meals and travel tied to these products, about $1,320 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 58 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.